A Pilot Study of the Safety and Tolerability of Etanercept in Patients with Alcoholic Hepatitis

American Journal of Gastroenterology

Volumn 99, Issue 2, 2004, Pages 255-260

  Menon, K V Narayanan ^b   Stadheim, Linda ^b   Kamath, Patrick S ^b   Wiesner, Russell H ^b   Gores, Gregory J ^b   Peine, Craig J ^b   Shah, Vijay ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INTERLEUKIN 6; PROTEIN P75; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; DISCRIMINANT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MALE; PATHOGENESIS; PILOT STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1442301516     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.04034.x     Document Type: Article

References (46)

1. Menon K, Gores G, Shah V. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001;76:1021-29.
2. Morgan M. The treatment of alcoholic hepatitis. Alcohol Alcohol 1996;31:117-34.
3. Morgan T, McClain C. Pentoxifylline and alcoholic hepatitis. Gastroenterology 2000;119:1787-91.
4. McCullough A, O'Connor J. Alcoholic liver disease: Proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998;93:2022-36.
5. McClain CJ. Tumor necrosis and alcoholic hepatitis. Hepatology 1991;14:394-96.
6. McClain C, Hill D, Schmidt J, et al. Cytokines and alcoholic liver disease. Semin Liver Dis 1993;13:170-82.
7. Arnon R, Esposti S, Zern M. Molecular biological aspects of alcohol-induced liver disease. Alcohol Clin Exp Res 1995;19:247-56.
8. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-51.
9. Thiele DL. Tumor necrosis factor, the acute phase response and the pathogenesis of alcoholic liver disease. Hepatology 1989;9:497-99.
10. Khoruts A, Stahnke L, McClain CJ, et al. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-76.
11. Hill D, Marsano L, Cohen D, et al. Increased plasma interleukin-6 activity in alcoholic hepatitis. J Lab Clin Med 1992;119:547-52.
12. Bird GL, Sheron N, Goka AK, et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-20.
13. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48.
14. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
15. Suffredini AF, Reda D, Banks SM, et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155:5038-45.
16. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
17. Sandbom W, Hanauer S, Katz S, et al. Etanercept for active Crohn's disease: A randomized double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
18. ten Cate R, van Suijlekom-Smit L, Brinkman D, et al. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology 2002;41:228-29.
19. Gorman J, Sack K, Davis JJ. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
20. Steensma D, Mesa R, Li C, et al. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study. Blood 2002;99:2252-54.
21. Keane J, Hershon S, Wise R, et al. Tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med 2001;345:1098-104.
22. Roach D, Bean A, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-27.
23. Maddrey W, Boitnott J, Bedine M, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-99.
24. Mendenhall CL, Anderson S, Weesner RE, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984;76:211-22.
25. Moreland L, Margolies G, Heck LJ, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
26. Carithers RJ, Herlong H, Diehl A, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial [see comments]. Ann Intern Med 1989;110:685-90.
27. Mendenhall C, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984;311:1464-70.
28. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2001;2:2.
29. Malinchoc M, Kamath P, Gordon F, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-71.
30. Kamath P, Wiesner R, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
31. Fleischmann R, Iqbal I, Nandeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: Focus on the benefits and risks of etanercept. Drug Saf 2002;25:173-97.
32. Moreland LW, Baumgarter SW, Tindall EA, et al. Long term efficacy and safety of TNF receptor (P75) Fc fusion protein (TNFR:Fc; Enbrel (TM)) in DMARD refractory rheumatoid arthritis (RA). Arthritis Rheum 1998;41(Suppl):S364.
33. Moreland L, Bucy R, Weinblatt M, et al. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002;103:13-21.
34. Phillips K, Husni M, Karlson E, et al. Experience with etanercept in an academic medical center: Are infection rates increased? Arthritis Rheum 2002;47:17-21.
35. Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med 2002;136:174.
36. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al. Short and long term outcome of severe alcohol induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial. Hepatology 2000;32:36-42.
37. Akriviadis E, Botla R, Briggs W, et al. Improved short-term survival with pentoxifylline treatment in severe alcoholic hepatitis [abstract]. Hepatology 1997;26:487.
38. Depew W, Boyer T, Omata M, et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980;78:524-9.
39. Mathurin P, Duchatelle V, Ramond M, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110:1847-53.
40. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326:507-12.
41. Lesesne H, Bozymski E, Fallon H. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978;74:169-73.
42. Immunex Corporation. Enbrel (etanercept) prescribing brochure, 1999.
43. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
44. Van Deventer S. Transmembran TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies on Crohn's disease. Gastroenterology 2001;121:1242-6.
45. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal anti body therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-25.
46. Spahr L, Rubbia-Brandt L, Frossard J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: A randomized controlled pilot study. J Hepatol 2002;37:448-55.